Premium Nahrungsergänzungsmittel | artgerecht

B-cell Depletion: Therapy & Mechanism

B-cell depletion refers to the targeted reduction or elimination of B-lymphocytes from the blood and tissues. It is used therapeutically in autoimmune diseases and certain blood cancers.

Regular tips about health Regular tips about health

Things worth knowing about "B-cell depletion"

B-cell depletion refers to the targeted reduction or elimination of B-lymphocytes from the blood and tissues. It is used therapeutically in autoimmune diseases and certain blood cancers.

What is B-cell Depletion?

B-cell depletion is a medical process in which B-lymphocytes – a specific subset of white blood cells that are part of the immune system – are deliberately removed or significantly reduced from the blood, bone marrow, or other tissues. B-lymphocytes (also called B-cells) play a central role in the immune response by producing antibodies. In certain diseases where B-cells produce harmful autoantibodies or grow uncontrollably, their targeted elimination becomes therapeutically beneficial.

Mechanism of Action

B-cell depletion is primarily achieved using monoclonal antibodies that bind specifically to surface proteins on B-cells. The most common target molecule is CD20, a protein expressed on the surface of mature B-cells. When a CD20-directed antibody – such as rituximab – binds to this molecule, the B-cell is destroyed through several mechanisms:

Antibody-dependent cell-mediated cytotoxicity (ADCC): Immune effector cells recognize the bound antibody and destroy the B-cell.
Complement activation: The complement system is activated, leading to lysis of the B-cell.
Direct induction of apoptosis: The antibody directly triggers programmed cell death in the B-cell.

In addition to CD20-directed antibodies, there are also agents that target other B-cell surface molecules such as CD19 or CD22.

Indications

Autoimmune Diseases

In autoimmune diseases, the immune system mistakenly produces antibodies against the body's own tissues. B-cell depletion can interrupt this process. Typical indications include:

Rheumatoid arthritis (inflammatory joint disease)
Multiple sclerosis (inflammatory disease of the nervous system)
Systemic lupus erythematosus (SLE)
ANCA-associated vasculitides (inflammatory blood vessel diseases)
Neuromyelitis optica spectrum disorders (NMOSD)

Hematological Malignancies

In B-cell lymphomas and other B-cell neoplasms (malignant B-cell diseases), B-cell depletion is used as part of chemotherapy regimens or as a standalone treatment. Examples include:

Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma
Chronic lymphocytic leukemia (CLL)

Key Medications for B-cell Depletion

The most well-known agents used for B-cell depletion include:

Rituximab (anti-CD20; the first approved monoclonal antibody of this type)
Obinutuzumab (second-generation anti-CD20)
Ofatumumab (anti-CD20)
Ocrelizumab (anti-CD20; approved for multiple sclerosis)
Ublituximab (anti-CD20)
Inebilizumab (anti-CD19)

Side Effects and Risks

Since B-cells are an essential component of the immune system, their depletion leads to a temporary weakening of immune defenses. Possible side effects include:

Increased susceptibility to infections, particularly bacterial and viral
Infusion-related reactions (fever, chills, blood pressure drops) with intravenous administration
Reactivation of latent infections (e.g., hepatitis B, tuberculosis)
Hypogammaglobulinemia (low antibody levels in the blood) with long-term therapy
Progressive multifocal leukoencephalopathy (PML) (a rare but serious brain infection)

Before initiating B-cell depletion therapy, screening for latent infections is typically performed and the vaccination status of the patient is reviewed.

Monitoring and Follow-up

Following B-cell depletion therapy, the number of B-cells in the blood is regularly monitored (using flow cytometry), along with immunoglobulin levels. B-cell recovery typically begins after 6–12 months, but may vary depending on the agent used and the individual response of the patient.

References

Pescovitz MD. - Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation, 2006.
Hauser SL et al. - Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2017.
Smolen JS et al. - EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.